Atossa Therapeutics Management
Management criteria checks 3/4
Atossa Therapeutics' CEO is Steve Quay, appointed in Apr 2009, has a tenure of 15.58 years. total yearly compensation is $2.36M, comprised of 30% salary and 70% bonuses, including company stock and options. directly owns 0.002% of the company’s shares, worth €3.09K. The average tenure of the management team and the board of directors is 3.8 years and 12.8 years respectively.
Key information
Steve Quay
Chief executive officer
US$2.4m
Total compensation
| CEO salary percentage | 30.0% |
| CEO tenure | 15.6yrs |
| CEO ownership | 0.002% |
| Management average tenure | 3.8yrs |
| Board average tenure | 12.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$27m |
| Jun 30 2024 | n/a | n/a | -US$26m |
| Mar 31 2024 | n/a | n/a | -US$30m |
| Dec 31 2023 | US$2m | US$706k | -US$30m |
| Sep 30 2023 | n/a | n/a | -US$30m |
| Jun 30 2023 | n/a | n/a | -US$32m |
| Mar 31 2023 | n/a | n/a | -US$28m |
| Dec 31 2022 | US$3m | US$706k | -US$27m |
| Sep 30 2022 | n/a | n/a | -US$24m |
| Jun 30 2022 | n/a | n/a | -US$21m |
| Mar 31 2022 | n/a | n/a | -US$22m |
| Dec 31 2021 | US$6m | US$659k | -US$21m |
| Sep 30 2021 | n/a | n/a | -US$28m |
| Jun 30 2021 | n/a | n/a | -US$26m |
| Mar 31 2021 | n/a | n/a | -US$23m |
| Dec 31 2020 | US$3m | US$601k | -US$22m |
| Sep 30 2020 | n/a | n/a | -US$13m |
| Jun 30 2020 | n/a | n/a | -US$13m |
| Mar 31 2020 | n/a | n/a | -US$16m |
| Dec 31 2019 | US$6m | US$601k | -US$17m |
| Sep 30 2019 | n/a | n/a | -US$17m |
| Jun 30 2019 | n/a | n/a | -US$17m |
| Mar 31 2019 | n/a | n/a | -US$25m |
| Dec 31 2018 | US$2m | US$582k | -US$23m |
| Sep 30 2018 | n/a | n/a | -US$23m |
| Jun 30 2018 | n/a | n/a | -US$22m |
| Mar 31 2018 | n/a | n/a | -US$11m |
| Dec 31 2017 | US$1m | US$520k | -US$11m |
Compensation vs Market: Steve's total compensation ($USD2.36M) is above average for companies of similar size in the German market ($USD782.05K).
Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.
CEO
Steve Quay (73 yo)
15.6yrs
Tenure
US$2,356,220
Compensation
Dr. Steven C. Quay, also known as Steve, M.D., Ph D., FCAP, has been the Chief Executive Officer and President of Atossa Therapeutics, Inc. (formerly known as Atossa Genetics Inc.) since April 30, 2009 and...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 15.6yrs | US$2.36m | 0.0021% € 3.1k | |
| Chief Financial Officer & Principal Accounting Officer | 3.8yrs | US$687.46k | 0% € 0 | |
| Senior Vice President of Administration & HR | 10.3yrs | no data | no data | |
| Vice President of Investor & Public Relations | 2.8yrs | no data | no data | |
| Interim Chief Medical Officer | 2.1yrs | no data | no data |
3.8yrs
Average Tenure
Experienced Management: YAG2's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 15.6yrs | US$2.36m | 0.0021% € 3.1k | |
| Independent Director | 10.7yrs | US$146.17k | 0% € 0 | |
| Independent Director | 12.8yrs | US$144.92k | 0.00020% € 292.5 | |
| Director | 15.6yrs | US$116.17k | 0.018% € 25.9k | |
| Independent Director | 13.3yrs | US$144.92k | 0.000080% € 117.0 | |
| Independent Director | less than a year | US$93.98k | 0.020% € 29.1k | |
| Independent Director | less than a year | no data | no data |
12.8yrs
Average Tenure
67yo
Average Age
Experienced Board: YAG2's board of directors are seasoned and experienced ( 12.8 years average tenure).